Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Lancet Gastroenterol Hepatol

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    December 2022
  1. ALLEGRETTI JR
    Should faecal microbiota transplantation be used earlier in the treatment framework?
    Lancet Gastroenterol Hepatol. 2022;7:1062-1063.
    PubMed    


    November 2022
  2. NOOR NM, Siegel C
    Partially randomised, patient preference trials for inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022;7:981-983.
    PubMed    


    October 2022
  3. ATIA O, Shavit-Brunschwig Z, Mould DR, Stein R, et al
    Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00307.
    PubMed     Abstract available


  4. QUAN J, Ma C, Panaccione R, Hracs L, et al
    Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Oct 25. pii: S2468-1253(22)00340.
    PubMed    


    September 2022
  5. SELIM R, Wellens J, Brann S, Marlow L, et al
    Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
    Lancet Gastroenterol Hepatol. 2022 Sep 21. pii: S2468-1253(22)00302.
    PubMed    


  6. ALEXANDER JL, Liu Z, Munoz Sandoval D, Reynolds C, et al
    COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Sep 8. pii: S2468-1253(22)00274.
    PubMed     Abstract available


  7. VERMEIRE S, Sands BE, Tilg H, Tulassay Z, et al
    ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00233.
    PubMed     Abstract available


  8. ATREYA R, Neurath MF
    Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022 Sep 5. pii: S2468-1253(22)00249.
    PubMed    


    August 2022
  9. TIAN H, Zhang S, Qin H, Li N, et al
    Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China.
    Lancet Gastroenterol Hepatol. 2022;7:702-703.
    PubMed    


    July 2022
  10. ANANTHAKRISHNAN AN, Kaplan GG, Bernstein CN, Burke KE, et al
    Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
    Lancet Gastroenterol Hepatol. 2022;7:666-678.
    PubMed     Abstract available


  11. MEIMA-VAN PRAAG EM, van Rijn KL, Wasmann KATGM, Snijder HJ, et al
    Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:617-626.
    PubMed     Abstract available


    June 2022
  12. WATERMEYER G, Awuku Y, Fredericks E, Epstein D, et al
    Challenges in the management of inflammatory bowel disease in sub-Saharan Africa.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00048.
    PubMed     Abstract available


  13. WATERMEYER G, Katsidzira L, Setshedi M, Devani S, et al
    Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis.
    Lancet Gastroenterol Hepatol. 2022 Jun 29. pii: S2468-1253(22)00047.
    PubMed     Abstract available


  14. ROSEIRA J, Estevinho MM, Bernardo S, Sousa P, et al
    Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503.
    PubMed    


  15. GENERE JR, Deepak P, Kochhar GS
    Reframing self-expandable metal stents for Crohn's strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503-504.
    PubMed    


  16. GELDOF J, Iqbal N, LeBlanc JF, Anandabaskaran S, et al
    Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
    Lancet Gastroenterol Hepatol. 2022;7:576-584.
    PubMed     Abstract available


    May 2022
  17. PARIGI TL, D'Amico F, Abreu MT, Rubin DT, et al
    Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Lancet Gastroenterol Hepatol. 2022;7:390-391.
    PubMed    


  18. THE LANCET GASTROENTEROLOGY HE
    Opacity over live vaccines in infants exposed to infliximab.
    Lancet Gastroenterol Hepatol. 2022;7:379.
    PubMed    


    April 2022
  19. WELLENS J, Brann S, Adams A, Marlow L, et al
    Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Apr 6. pii: S2468-1253(22)00120.
    PubMed    


  20. HAIFER C, Paramsothy S, Kaakoush NO, Leong RW, et al
    Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2022;7:286-287.
    PubMed    


  21. YUAN TY, Rajesh R, Tan M
    Oral faecal microbiota transplantation in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022;7:286.
    PubMed    


  22. UNGARO RC, Colombel JF
    Treat to target with ustekinumab for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:276-277.
    PubMed    


  23. DANESE S, Vermeire S, D'Haens G, Panes J, et al
    Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Lancet Gastroenterol Hepatol. 2022;7:294-306.
    PubMed     Abstract available


  24. LORAS C, Andujar X, Gornals JB, Sanchiz V, et al
    Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:332-341.
    PubMed     Abstract available


  25. GOREN I, Rieder F
    Endoscopic interventions for stricturing Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:279-280.
    PubMed    


  26. SCHULBERG JD, Wright EK, Holt BA, Hamilton AL, et al
    Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2022;7:318-331.
    PubMed     Abstract available


    March 2022
  27. MATSUOKA K, Watanabe M, Ohmori T, Nakajima K, et al
    AJM300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2022 Mar 30. pii: S2468-1253(22)00022.
    PubMed     Abstract available


  28. KOTZE PG, Heuthorst L, Lightner AL, Damiao AOMC, et al
    New insights on the surgical management of ulcerative colitis in the 21st century.
    Lancet Gastroenterol Hepatol. 2022 Mar 29. pii: S2468-1253(22)00001.
    PubMed     Abstract available


    February 2022
  29. KUENZIG ME, Widdifield J, Bernatsky S, Kaplan GG, et al
    Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.
    Lancet Gastroenterol Hepatol. 2022 Feb 22. pii: S2468-1253(22)00054.
    PubMed    


  30. ALEXANDER JL, Kennedy NA, Ibraheim H, Anandabaskaran S, et al
    COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Feb 3. pii: S2468-1253(22)00005.
    PubMed     Abstract available


  31. PAPAMICHAEL K, Afif W, Drobne D, Dubinsky MC, et al
    Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Lancet Gastroenterol Hepatol. 2022;7:171-185.
    PubMed     Abstract available


  32. OZPOLAT HT, Baran B, Akyuz F
    Septic arthritis: a presentation of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:196.
    PubMed    


    January 2022
  33. GUILLO L, Abreu M, Panaccione R, Sandborn WJ, et al
    Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
    Lancet Gastroenterol Hepatol. 2022 Jan 17. pii: S2468-1253(21)00297.
    PubMed     Abstract available


  34. SASSON AN
    A whole-food exclusion diet as monotherapy for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:6-7.
    PubMed    


  35. SHEN B, Kochhar GS, Rubin DT, Kane SV, et al
    Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2022;7:69-95.
    PubMed     Abstract available


  36. YANAI H, Levine A, Hirsch A, Boneh RS, et al
    The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:49-59.
    PubMed     Abstract available


    December 2021
  37. HAIFER C, Paramsothy S, Kaakoush NO, Saikal A, et al
    Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00400.
    PubMed     Abstract available


  38. FISCHER M, Khoruts A
    Oral lyophilised microbiota for the treatment of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00433.
    PubMed    


  39. AHMED W, Lukin DJ
    A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:973-975.
    PubMed    


  40. SO D, Tuck CJ
    Plant-based diets in gastrointestinal disorders: something, nothing, or everything?
    Lancet Gastroenterol Hepatol. 2021;6:992.
    PubMed    


  41. THOMAS H
    UEG Week Virtual 2021.
    Lancet Gastroenterol Hepatol. 2021;6:990.
    PubMed    


  42. SINGH S, Murad MH, Fumery M, Sedano R, et al
    Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021;6:1002-1014.
    PubMed     Abstract available


    November 2021
  43. LASA JS, Olivera PA, Danese S, Peyrin-Biroulet L, et al
    Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00377.
    PubMed     Abstract available


  44. MA C, Choi MY
    Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00432.
    PubMed    


  45. TAKENAKA K, Fujii T, Kawamoto A, Suzuki K, et al
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00372.
    PubMed     Abstract available


  46. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    PubMed     Abstract available


  47. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    PubMed     Abstract available


  48. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    PubMed     Abstract available


  49. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    PubMed     Abstract available


  50. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    PubMed    


  51. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    PubMed    


  52. ASWANI-OMPRAKASH T, Sharma V, Bishu S, Balasubramaniam M, et al
    Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
    Lancet Gastroenterol Hepatol. 2021;6:884-885.
    PubMed    


    October 2021
  53. SELIM R, Wellens J, Marlow L, Satsangi JJ, et al
    SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
    Lancet Gastroenterol Hepatol. 2021 Oct 13. pii: S2468-1253(21)00347.
    PubMed    


  54. ALEXANDER JL, Selinger CP, Powell N
    Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Oct 12. pii: S2468-1253(21)00374.
    PubMed    


  55. SHEN B, Kochhar GS, Kariv R, Liu X, et al
    Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2021;6:826-849.
    PubMed     Abstract available


  56. HANAUER S, Liedert B, Balser S, Brockstedt E, et al
    Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2021;6:816-825.
    PubMed     Abstract available


    September 2021
  57. SHEN B, Bortlik M, Bruining DH, Coelho-Prabhu N, et al
    Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:691-692.
    PubMed    


  58. SYAL G, Fleshner PR, Melmed GY
    Endoscopic evaluation after surgery in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:690-691.
    PubMed    


  59. KOBAYASHI T
    Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:688.
    PubMed    


  60. TAN M, Ng V, Lim CT, Leow WQ, et al
    Stringent criteria for withdrawal of biologics in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021;6:687-688.
    PubMed    


    August 2021
  61. FIORINO G, Allocca M, Danese S
    Adalimumab biosimilar in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Aug 10. pii: S2468-1253(21)00266.
    PubMed    


  62. GEYL S, Guillo L, Laurent V, D'Amico F, et al
    Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2021;6:659-667.
    PubMed     Abstract available


    July 2021
  63. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
    The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
    PubMed     Abstract available


  64. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:523.
    PubMed    


  65. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:523-524.
    PubMed    


  66. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.
    PubMed    


    June 2021
  67. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    PubMed     Abstract available


    May 2021
  68. ALEXANDER JL, Powell N
    SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
    Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
    PubMed    


  69. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
    Defining difficult-to-treat inflammatory bowel disease: why and how.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
    PubMed    


  70. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
    Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
    PubMed     Abstract available


  71. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
    The impact of SARS-CoV-2 variants on IBD management.
    Lancet Gastroenterol Hepatol. 2021;6:343-344.
    PubMed    


    April 2021
  72. UNGAR B
    Infliximab discontinuation in patients with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
    PubMed    


  73. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
    Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
    PubMed     Abstract available


  74. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
    Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
    PubMed     Abstract available


    March 2021
  75. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
    Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
    PubMed     Abstract available


  76. KEEFER L
    What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
    PubMed    


  77. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
    The ileoanal pouch: the next frontier in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:164-165.
    PubMed    


  78. JENA A, Jha DK, Sharma V
    Distinguishing intestinal tuberculosis from Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:159.
    PubMed    


  79. BANERJEE R, Pal P
    Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:159-160.
    PubMed    


    February 2021
  80. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
    Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
    PubMed     Abstract available


  81. SHEN B
    Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
    PubMed    


  82. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
    From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Lancet Gastroenterol Hepatol. 2021;6:88-89.
    PubMed    


    January 2021
  83. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
    PubMed     Abstract available


    December 2020
  84. NG SC, Mak JWY, Pal P, Banerjee R, et al
    Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
    PubMed     Abstract available


  85. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
    Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
    PubMed     Abstract available


  86. STRID H
    Prevalence of IBS-type symptoms in IBD.
    Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
    PubMed    


    November 2020
  87. AZIZ I, Simren M
    The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
    Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
    PubMed     Abstract available


    October 2020
  88. MA C, Panaccione R
    Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
    PubMed    


  89. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
    Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
    PubMed     Abstract available


  90. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
    IBD in the COVID-19 era: the value of international collaboration.
    Lancet Gastroenterol Hepatol. 2020;5:887-888.
    PubMed    


  91. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
    Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2020;5:900-907.
    PubMed     Abstract available


  92. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
    Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
    PubMed     Abstract available


    May 2020
  93. LOUGHMAN A, Staudacher HM
    Treating the individual with diet: is gut microbiome testing the answer?
    Lancet Gastroenterol Hepatol. 2020;5:437.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: